PVLA: Backing QTORIN as a First-in-Class Option for Rare Vascular Skin Disorders
Palvella’s QTORIN topical platform is targeting multiple rare dermatologic and vascular malformations with no FDA-approved therapies. Recent positive Phase 2 data, a completed upsized $230M offering and a small public float create a volatile but actionable setup. This trade proposes a long position at current levels with a defined stop and upside t…